Emicizumab in the Treatment of Hemophilia A. Characteristics and clinical application
DOI:
https://doi.org/10.12775/JEHS.2025.81.66759Keywords
Hemophilia A, emicizumab, pharmacokinetics, ABR, HAVEN trials, factor VIIIAbstract
Introduction: Hemophilia A is an inherited bleeding disorder caused by a congenital deficiency of factor VIII. It is characterized by a tendency for prolonged and excessive bleeding, both spontaneous and trauma-induced. The treatment of hemophilia A involves the use of factor VIII replacement therapy. In recent years, emicizumab-a modern, bispecific monoclonal antibody- has gained significant attention as an alternative to traditional treatment methods.
Materials and methods : A total of 30 articles were analyzed, sourced from publicly available databases such as PubMed and Google Scholar. The selection focused on publications addressing molecular structure, pharmacokinetics, and treatment efficacy. The majority of the cited sources were published in English.
State of knowledge: In this article, we will discuss the mechanism of action of emicizumab, its pharmacokinetics, and the benefits of its use in the treatment of hemophilia A, including a comparison with traditional therapies. The results of clinical trials will also be presented, confirming its efficacy, safety, and patient satisfaction, including in the context of treating patients with FVIII inhibitors.The goal is to present the effectiveness, safety, mechanism of action, and pharmacokinetic profile of emicizumab in bleeding prophylaxis for patients with hemophilia A.
Conclusions: Emicizumab is a groundbreaking prophylactic treatment for hemophilia A, effective both in patients with and without factor VIII inhibitors, by mimicking the function of factor VIIIa. Clinical trials HAVEN 1–4 demonstrated the drug’s high efficacy in reducing bleeds and significantly lowering annual bleeding rates. Emicizumab has a favorable pharmacokinetic profile, allowing for infrequent dosing and improving therapy comfort compared to traditional treatment.
References
1. Szczeklik A. Gajewski P. Interna Szczeklika 2024. Medycyna Praktyczna, Kraków 2024.
2. Lenting PJ, Denis V, Christophe OD. Perspective Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017; Vol. 130: 2463-67. https://doi.org/10.1182/blood-2017-08-801662
3. Yada K, Nogami K. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab. Arteriosclerosis, Thrombosis, and Vascular Biology. Lippincott Williams and Wilkins; 2020; Vol. 40:1148–54. https://doi.org/10.1161/ATVBAHA.120.312919
4. Summary of product characteristics https://ec.europa.eu/health/documents/community register/2018/20180223140159/anx_140159_en.pdf
5. Yoneyama K, Schmitt C, Portron A, Kiialainen A, Kotani N, Jaminion F, et al. Clinical pharmacology of emicizumab for the treatment of hemophilia A. Expert Review of Clinical Pharmacology. Taylor and Francis Ltd. 2023; Vol. 16: 775–90. https://doi.org/10.1080/17512433.2023.2243213
6. Voorberg J, Postmus T, Schols S. Next generation FVIII mimetic bispecific antibody for hemophilia A. Journal of Thrombosis and Haemostasis. John Wiley and Sons Inc. 2022;Vol. 20:1301–5. https://doi.org/10.1111/jth.15705
7. Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013; 8(2):57479. https://doi.org/10.1371/journal.pone.0057479
8. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. New England Journal of Medicine. 2017 Aug 31; 377(9):809–18. https://doi.org/10.1371/journal.pone.0057479
9. Scott LJ, Kim ES. Emicizumab-kxwh: First Global Approval. Drugs. https://pubmed.ncbi.nlm.nih.gov/29357074/
10. Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. Thromb Haemost. 2020 Oct 1; 120(10):1357–70. https://doi.org/10.1055/s-0040-1714279
11. Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. New England Journal of Medicine. 2018 Aug 30; 379(9):811–22. https://doi.org/10.1056/nejmoa1803550
12. Lillicrap D, Fijnvandraat K, Young G, Mancuso ME. Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. https://www.tandfonline.com/doi/abs/10.1080/17474086.2020.1739518
13. Starting Hemlibra Quick Reference Guide https://www.hemlibra-hcp.com/dosing-and administration/dosing.html (dostęp: 2025.05.10).
14. Schmitt C, Adamkewicz JI, Xu J, Petry C, Catalani O, Young G, et al. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Thromb Haemost. 2021 Mar 1;121(3):351–60. https://doi.org/10.1055/s-0040-1717114
15. Kotani N, Yoneyama K, Kawakami N, Shimuta T, Fukase H, Kawanishi T. Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers. Clin Pharmacol Drug Dev. 2019 Aug 1;8(6):702–12. https://doi.org/10.1002/cpdd.617
16. Windyga J. Emicizumab in severe hemophilia A. Acta Haematol Pol. https://journals.viamedica.pl/acta_haematologica_polonica/article/view/AHP.2021.0079
17. Nogami K. Bispecific antibody mimicking factor VIII. Thromb Res. https://www.thrombosisresearch.com/action/showFullText?pii=S0049384816303619
18. Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. https://pmc.ncbi.nlm.nih.gov/articles/PMC6908828/
19. Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. https://www.thelancet.com/action/showFullText?pii=S2352302619300547
20. Escuriola Ettingshausen C, Eberl W, Eichler H, Fischer R, Hart C, Holstein K, et al. Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary. Ther Adv Hematol. 2024 Jan 1;15. https://doi.org/10.1177/20406207241295653
21. Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. http://ashpublications.org/blood/article-pdf/137/16/2231/1805347/bloodbld2020009217.pdf
22. Powell JS, Josephson NC, Quon D, Ragni M V, Cheng G, Li E, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients Current factor VIII (FVIII) products display a half-life (t 1/2 ) of 8-12 hours, requiring frequent intravenous injections for pro-phylaxis and treatment of patients with hemophilia. http://ashpublications.org/blood/article pdf/119/13/3031/1348603/zh801312003031.pdf
23. Yoneyama K, Schmitt C, Kotani N, Levy GG, Kasai R, Iida S, et al. A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. Clin Pharmacokinet. 2018 Sep 1;57(9):1123–34. https://doi.org/10.1007/s40262-017-0616-3
24. Kiialainen A, Adamkewicz JI, Petry C, Oldenburg J, Pipe SW, Young G, et al. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks. Res Pract Thromb Haemost. 2024 Jan 1;8(1). https://doi.org/10.1016/j.rpth.2023.102306
25. Franchini M, Mannucci PM. The More Recent History of Hemophilia Treatment. Semin Thromb Hemost. 2022 Nov 1;48(8):904–10. https://doi.org/10.1055/s-0042-1756188
26. Kempton C, Trask P, Parnes A, Niggli M, Campinha-Bacote A, U. Callaghan M, et al. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021 Mar 1;27(2):221–8. https://doi.org/10.1111/hae.14222
27. Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. Journal of Thrombosis and Haemostasis. Elsevier B.V. 2023; Vol. 21: p. 403–12. https://doi.org/10.1016/j.jtha.2022.12.029
28. Lewandowska M, Nasr S, Shapiro AD. Emerging Therapies in Hemophilia: Improving Equitable Access to Care. Journal of Blood Medicine. Dove Medical Press Ltd. 2025; Vol.16:95–115. https://doi.org/10.2147/jbm.s490588
29. Parnes A. In hemophilia, it just keeps getting better. Blood. Elsevier B.V. 2021; Vol. 137:2135–6. https://doi.org/10.1182/blood.2020010238
30. Howard M, McKinley D, Sanabria F, Ko R, Nissen F. Evaluation of the Safety of Emicizumab Prophylaxis in Persons with Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic Microangiopathies. Blood. 2021 Nov 5;138:3186. https://doi.org/10.1182/blood-2021-146147
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ilona Bednarek, Sylwia Lach, Aleksandra Kowalczyk, Adrian Pączek, Paweł Dyczek, Julia Hofman, Wiktoria Staniszewska, Olaf Jadanowski, Karol Seweryn Błąd
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 42
Number of citations: 0
